Lyell Immunopharma price to sales ratio LYEL

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 12.4×; Feb 2024
Peer median: 1.4×

Lyell Immunopharma's price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Feb 2024, at 12.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	12.4×	9.3×	12.4×
2023	10.1×	5.9×	21.7×
2022	22.1×	19.4×	189×

Against its peers

Companies in Drug Manufacturers - General nearest Lyell Immunopharma's size, closest first, today.

Company	Price to sales ratio
LYELLyell Immunopharma	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
LFVNLifevantage	0.4×
COLLCollegium Pharmaceutical	0.9×
SPROSpero Therapeutics	1.4×
ABUSArbutus Biopharma	4.6×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Lyell Immunopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.